Bio-Rad Introduces Liquichek Opiate Control 

HERCULES, CA – April 12, 2010
– Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multi-national manufacturer and distributor of life science research and clinical diagnostic products, today announced the launch of Liquichek™ Opiate Control. Liquichek Opiate Control is a liquid, third party control designed to monitor urine toxicology testing procedures for a broad class of opioids.

Liquichek Opiate Control is prepared from human urine and contains popular drugs or drug metabolites commonly measured in pain management, addiction therapy or drug abuse. Routine use of Liquichek Opiate Control provides laboratories the ability to monitor the precision of opioid drug testing procedures and helps ensure quality on an ongoing basis. The product is supplied in liquid (frozen) form that can be tested in the same manner as a patient specimen. It is offered in two individual levels: one below and one above most assay cutoffs

The Unity™ Interlaboratory Program is available for use with the Liquichek Opiate Control. Unity Real Time®, an expert QC data management software solution designed to improve the effectiveness of quality control processes, is also available.

With over 30 years experience as a leading provider of quality control products, Bio-Rad offers superior technical support and troubleshooting assistance.

For more information, please call 1-800-2-BIORAD (1-800-224-6723) or visit

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,800 people globally and had revenues of nearly $1.8 billion in 2009. For more information, visit

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information contact:
Lillian Valletta, Product Manager
Bio-Rad Laboratories, Inc.


Log In / Register

Log In / Register